美股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

Arin Tactical Tail Risk ETF

91.26

0.0000

成交量：- -

成交額：14.22萬

市值：8,935.67萬

市盈率：- -

高：91.26

開：91.26

低：91.26

收：91.26

52周最高：91.29

52周最低：45.10

股本：97.91萬

流通股本：95.91萬

量比：- -

換手率：- -

股息：- -

股息率：- -

淨資產收益率：--

總資產收益率：--

市淨率：--

市盈率(LYR):- -

資料載入中...

總覽公司新聞資訊公告

概念

no data

沒有相關數據

資金流向

資金流入：

資金流出：

新聞資訊

從「跑不動」到「有藥治」：「澱粉人」治療即將迎來重大突破

萬諾維®在華獲批用於治療成人遺傳性轉甲狀腺素蛋白澱粉樣變性多發性神經病（ATTRv-PN）患者

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"Easy breezy. No more feesies.","description":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","keywords":"老虎國際,美股交易,港股交易,交易美股,股票信息,股價,美股行情,美股打新,港股打新,IPO打新,購買美股,全球投資","social":{"ogDescription":"Tiger Trade is a mobile trading app offering real time data, low commission fees and a free demo account. Download now to start investing in ETFs, options and the global share market.","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.itiger.com/hant/stock/ATTR"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"NZL","license":"TBKIWI","edition":"fundamental","symbol":"ATTR","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","market":"US","secType":"STK","nameCN":"Arin Tactical Tail Risk ETF","latestPrice":91.2598,"timestamp":1770744201454,"preClose":91.2598,"halted":0,"volume":0,"delay":0,"changeRate":0,"floatShares":959146,"shares":979146,"eps":0,"marketStatus":"交易中","change":0,"latestTime":"02-10 12:23:21 EST","open":91.2598,"high":91.2598,"low":91.2598,"amount":142214.76971999998,"amplitude":0,"askPrice":91.29,"askSize":100,"bidPrice":91.25,"bidSize":500,"shortable":3,"etf":1,"ttmEps":0,"tradingStatus":2,"nextMarketStatus":{"tag":"盤後交易","tradingStatus":3,"beginTime":1770757200000},"marketStatusCode":2,"adr":0,"exchange":"CBOE","adjPreClose":91.2598,"sharesOutstanding":979146,"nav":91.24,"aum":89337281.04,"bidAskSpread":0,"volumeRatio":0},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"ATTR\",,,,,undefined,":{"symbol":"ATTR","floatShares":959146,"roa":"--","roe":"--","lyrEps":0,"shares":979146,"dividePrice":0,"high":91.2598,"amplitude":0,"preClose":91.2598,"low":91.2598,"week52Low":45.1,"pbRate":"--","week52High":91.29,"institutionHeld":0,"latestPrice":91.2598,"committee":0.666667,"eps":0,"divideRate":0,"volume":0,"delay":0,"ttmEps":0,"open":91.2598,"prevYearClose":90.4492,"prevWeekClose":91.2003,"prevMonthClose":91.0958,"prevQuarterClose":90.4492,"fiveDayClose":91.1197,"twentyDayClose":90.83,"sixtyDayClose":90.5782},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/ATTR\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"ATTR\",market:\"US\",,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/estimate/recommendation\",params:#symbol:\"ATTR\",market:\"US\",delay:false,,,undefined,":{},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"ATTR\",pageSize:4,pageCount:1,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2594239863","title":"從「跑不動」 到 「有藥治」：「澱粉人」治療即將迎來重大突破","url":"https://stock-news.laohu8.com/highlight/detail?id=2594239863","media":"上观新闻","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594239863?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 18:09","pubTimestamp":1766657357,"startTime":"0","endTime":"0","summary":"2016年的一天，老王（化名）的生活被一场突如其来的变化打破——他忽然发现自己再也跑不动了，脚腕像灌了铅般沉重。这份不适并未止步，反而一步步侵袭全身：从最初的四肢无力，逐渐发展为呼吸困难、肌肉萎缩。为了查明病因，他辗转七家医院、问诊二十余位医生，历经整整五年的漫长求索，才终于被明确诊断为转甲状腺素蛋白淀粉样变性（ATTR）。","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202512253601978880.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["ATTR"],"gpt_icon":0},{"id":"2594236078","title":"萬諾維®在華獲批用於治療成人遺傳性轉甲狀腺素蛋白澱粉樣變性多發性神經病（ATTRv-PN）患者","url":"https://stock-news.laohu8.com/highlight/detail?id=2594236078","media":"美通社","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2594236078?lang=zh_tw&edition=fundamental","pubTime":"2025-12-25 17:10","pubTimestamp":1766653800,"startTime":"0","endTime":"0","summary":"依普隆特生钠是中国首个且目前唯一获批用于ATTRv-PN治疗的基因沉默剂。\" 依普隆特生钠已在美国和欧盟获批用于治疗ATTRv-PN，并正在全球更多国家和地区推进审批进程。依普隆特生钠目前正在开展CARDIO-TTRansform III期临床研究，旨在评估其用于治疗成人转甲状腺素蛋白心脏淀粉样变心肌病的疗效。作为RNA靶向治疗药物，它可在肝脏源头减少TTR蛋白的产生，因而具有潜力用于治疗各类型的转甲状腺素蛋白介导的淀粉样变性。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://wwwold.prnasia.com/story/archive/4853711_ZH53711_1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"prnasia","symbols":["BK4585","ATTR","LU0320765992.SGD","CV","LU0889565916.HKD","BK4588","LU1829250122.USD","BK4568","LU0109394709.USD","LU2456880835.USD","BK4082","AZN","HF","LU2417539215.USD","LU2462157665.USD","BK4007","LU2236285917.USD"],"gpt_icon":0}],"pageSize":4,"totalPage":1,"pageCount":1,"totalSize":2,"code":"91000000","status":"200"}],"@#url:\"https://hq.skytigris.cn/market/plate/belongs/ATTR\",params:#limit:6,delay:false,,,undefined,":[]}}